about
Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors.Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy.An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors.Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer.Proteogenomic integration reveals therapeutic targets in breast cancer xenografts4-step 4-h carboplatin desensitization protocol for patients with gynecological malignancies showing platinum hypersensitivity: a retrospective study.Establishment of the acute myeloid leukemia cell line Kasumi-6 from a patient with a dominant-negative mutation in the DNA-binding region of the C/EBPalpha gene.Cisplatin with dose-dense paclitaxel before and after radical hysterectomy for locally advanced cervical cancer: a prospective multicenter phase II trial with a dose-finding study.Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.Clinical characteristics and outcomes of women with stage IV endometrial cancer.Transcriptional CCND1 expression as a predictor of poor response to neoadjuvant chemotherapy with trastuzumab in HER2-positive/ER-positive breast cancer.Applicability of the concept of “platinum sensitivity” to recurrent endometrial cancer: The SGSG-012/GOTIC-004/Intergroup studyIntegrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast CancerSecond platinum therapy in patients with uterine cervical cancer previously treated with platinum chemotherapyA Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors
P50
Q33392841-6767447E-1756-43E9-A54E-CCDAE3E6C9FCQ34059719-04302E59-9828-46DF-A3FB-4F8A6C07F514Q35996229-75E8D482-7F03-46A1-A4B0-B88FF4DE202BQ36072056-5BEE2E8B-B433-4F94-84CA-1639E87E63A4Q37736390-15AA32E2-66A8-40E5-89C6-AF2D088D185CQ38230264-14D7E6AB-7E2D-4E1F-8BEC-765232513277Q40679981-49598D2C-60C5-48EE-A06D-D13E7AAAB8FFQ48169923-0CAE180C-FCFB-4ECE-A3A1-A9F767B06F70Q51740985-FCA9C86B-0BEA-47D1-B20F-7EC698812E8AQ53353041-63DDF174-CFF0-4FC5-98D0-9424839689A7Q54324226-DB074109-9956-4F6C-B74D-658313D044FEQ63199198-C9F9898C-CD34-44C5-B45F-FCBF6B959EE4Q64123416-A592E055-9F91-4FFF-BCCF-461897DDA748Q82059592-E998E908-754D-4059-ADCF-7BFF052F39B7Q82829017-2450C5D1-8657-46EA-BEB6-0FDDDC95E2BD
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Maki Tanioka
@ast
Maki Tanioka
@en
Maki Tanioka
@es
Maki Tanioka
@nl
Maki Tanioka
@sl
type
label
Maki Tanioka
@ast
Maki Tanioka
@en
Maki Tanioka
@es
Maki Tanioka
@nl
Maki Tanioka
@sl
prefLabel
Maki Tanioka
@ast
Maki Tanioka
@en
Maki Tanioka
@es
Maki Tanioka
@nl
Maki Tanioka
@sl
P106
P31
P496
0000-0002-6558-2246